Remus Pharmaceuticals Ltd
Remus Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
3 of 3 strong
The short version
US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions. Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business.
From Remus Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions.
- Both US subsidiary and standalone/emerging market businesses expected to grow proportionately, maintaining or slightly adjusting revenue shares.
- Emerging market revenues currently ~20%; management anticipates this to increase to 25-30% over time as B2C segment grows rapidly.
- B2C business increased from 4% to 13% of revenues in H1 FY26; targeted to reach 18-20% by end-FY26 and 20-25% within next 1.5 years.
- Overall revenue growth supported by expansion into new geographies including Algeria, Kenya, Chile, Dominican Republic, and African markets.
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Remus Pharmaceuticals is actively expanding its international footprint, including recent entry into Algeria and plans for subsidiary establishments in new countries such as Kenya, Chile, and Dominican Republic.
- The company is focusing on building its B2C segment, including launching new products like Rivastigmine patches and other dermal patches, indicating investment in product development.
- They are setting up a new subsidiary for clinical trials and research services, which will contribute to future operational growth.
- Investments in technology transfer and licensing deals with local manufacturers (e.g., Algeria) are part of strategic efforts to enhance manufacturing collaborations and royalties.
2 more points from Remus Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Remus Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Remus Pharma.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q2 FY26 results?
US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions. Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business.
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 24.5 with a market cap of ₹906 Cr. Investors should review the full earnings analysis for detailed insights.
Is Remus Pharmaceuticals Ltd planning capital expenditure?
Remus Pharmaceuticals is actively expanding its international footprint, including recent entry into Algeria and plans for subsidiary establishments in new countries such as Kenya, Chile, and Dominican Republic.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.